Alcon, the eye-care business that Novartis AG acquired for more than $50 billion, is now weighing on Europe’s second-largest drugmaker. After more than a year of efforts to turn around the business, the Swiss company on Wednesday said it was considering all options for the embattled division, including a spinoff or initial public offering.